Skip to main content
Top
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Research

Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs)

Authors: Joachim Denner, Debora Mihica, Danny Kaulitz, Christa-Maria Schmidt

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

Despite enormous difficulties to induce antibodies neutralizing HIV-1, especially broadly neutralizing antibodies directed against the conserved membrane proximal external region (MPER) of the transmembrane envelope protein, such antibodies can be easily induced in the case of gammaretroviruses, among them the porcine endogenous retroviruses (PERVs). In addition to neutralizing antibodies directed against the transmembrane envelope protein p15E, neutralizing antibodies were also induced by immunization with the surface envelope protein gp70. PERVs represent a special risk for xenotransplantation using pig tissues or organs since they are integrated in the genome of all pigs and infect human cells and a vaccine may protect from transmission to the recipient. To investigate the effect of simultaneous immunization with both proteins in detail, a study was performed in hamsters. Gp70 and p15E of PERV were produced in E. coli, purified and used for immunization. All animals developed binding antibodies against the antigens used for immunization. Sera from animals immunized with p15E recognized epitopes in the MPER and the fusion peptide proximal region (FPPR) of p15E. One MPER epitope showed a sequence homology to an epitope in the MPER of gp41 of HIV-1 recognized by broadly neutralizing antibodies found in HIV infected individuals. Neutralizing antibodies were detected in all sera. Most importantly, sera from animals immunized with gp70 had a higher neutralizing activity when compared with the sera from animals immunized with p15E and sera from animals immunized with gp70 together with p15E had a higher neutralizing activity compared with sera from animals immunized with each antigen alone. These immunization studies are important for the development of vaccines against other retroviruses including the human immunodeficiency virus HIV-1.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P, Protocol G Principal Investigators: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011, 477: 466-470. 10.1038/nature10373.PubMedPubMedCentralCrossRef Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P, Protocol G Principal Investigators: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011, 477: 466-470. 10.1038/nature10373.PubMedPubMedCentralCrossRef
2.
go back to reference Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010, 329: 856-861. 10.1126/science.1187659.PubMedPubMedCentralCrossRef Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010, 329: 856-861. 10.1126/science.1187659.PubMedPubMedCentralCrossRef
3.
go back to reference Montero M, van Houten NE, Wang X, Scott JK: The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008, 72: 54-84. 10.1128/MMBR.00020-07.PubMedPubMedCentralCrossRef Montero M, van Houten NE, Wang X, Scott JK: The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008, 72: 54-84. 10.1128/MMBR.00020-07.PubMedPubMedCentralCrossRef
4.
go back to reference Fiebig U, Stephan O, Kurth R, Denner J: Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation?. Virology. 2003, 307: 406-413. 10.1016/S0042-6822(02)00140-X.PubMedCrossRef Fiebig U, Stephan O, Kurth R, Denner J: Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation?. Virology. 2003, 307: 406-413. 10.1016/S0042-6822(02)00140-X.PubMedCrossRef
5.
go back to reference Langhammer S, Fiebig U, Kurth R, Denner J: Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine. 2005, 23: 3341-3348. 10.1016/j.vaccine.2005.01.091.PubMedCrossRef Langhammer S, Fiebig U, Kurth R, Denner J: Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine. 2005, 23: 3341-3348. 10.1016/j.vaccine.2005.01.091.PubMedCrossRef
6.
go back to reference Langhammer S, Hubner J, Kurth R, Denner J: Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology. 2006, 117: 229-237. 10.1111/j.1365-2567.2005.02291.x.PubMedPubMedCentralCrossRef Langhammer S, Hubner J, Kurth R, Denner J: Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology. 2006, 117: 229-237. 10.1111/j.1365-2567.2005.02291.x.PubMedPubMedCentralCrossRef
7.
go back to reference Langhammer S, Fiebig U, Kurth R, Denner J: Increased neutralizing antibody response after simultaneous immunization with Leucogen and the feline leukemia virus transmembrane protein. Intervirology. 2010, 54: 78-86.PubMedCrossRef Langhammer S, Fiebig U, Kurth R, Denner J: Increased neutralizing antibody response after simultaneous immunization with Leucogen and the feline leukemia virus transmembrane protein. Intervirology. 2010, 54: 78-86.PubMedCrossRef
8.
go back to reference Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J: Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge. Antiviral Res. 2011, 89: 119-123. 10.1016/j.antiviral.2010.11.011.PubMedCrossRef Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J: Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge. Antiviral Res. 2011, 89: 119-123. 10.1016/j.antiviral.2010.11.011.PubMedCrossRef
9.
go back to reference Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J: Transspecies transmission of the endogenous koala retrovirus. J Virol. 2006, 80: 5651-5654. 10.1128/JVI.02597-05.PubMedPubMedCentralCrossRef Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J: Transspecies transmission of the endogenous koala retrovirus. J Virol. 2006, 80: 5651-5654. 10.1128/JVI.02597-05.PubMedPubMedCentralCrossRef
10.
go back to reference Wilson CA: Porcine endogenous retroviruses and xenotransplantation. Cell Mol Life Sci. 2008, 65: 3399-3412. 10.1007/s00018-008-8498-z.PubMedCrossRef Wilson CA: Porcine endogenous retroviruses and xenotransplantation. Cell Mol Life Sci. 2008, 65: 3399-3412. 10.1007/s00018-008-8498-z.PubMedCrossRef
11.
go back to reference Denner J, Tönjes RR: Infection barriers to succesful xenbotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev. 2012, 25: 318-343. 10.1128/CMR.05011-11.PubMedPubMedCentralCrossRef Denner J, Tönjes RR: Infection barriers to succesful xenbotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev. 2012, 25: 318-343. 10.1128/CMR.05011-11.PubMedPubMedCentralCrossRef
12.
go back to reference Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, Denner J: Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Virology. 2011, 411: 78-86. 10.1016/j.virol.2010.12.032.PubMedCrossRef Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, Denner J: Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Virology. 2011, 411: 78-86. 10.1016/j.virol.2010.12.032.PubMedCrossRef
13.
go back to reference Fiebig U, Eschricht M, Schmolke M, Kurth R, Denner J: Mode of interaction between the HIV-1 neutralizing monoclonal antibody 2F5 and its epitope. AIDS. 2009, 23: 887-895. 10.1097/QAD.0b013e3283292153.PubMedCrossRef Fiebig U, Eschricht M, Schmolke M, Kurth R, Denner J: Mode of interaction between the HIV-1 neutralizing monoclonal antibody 2F5 and its epitope. AIDS. 2009, 23: 887-895. 10.1097/QAD.0b013e3283292153.PubMedCrossRef
14.
go back to reference Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001, 75: 10892-10905. 10.1128/JVI.75.22.10892-10905.2001.PubMedPubMedCentralCrossRef Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001, 75: 10892-10905. 10.1128/JVI.75.22.10892-10905.2001.PubMedPubMedCentralCrossRef
15.
go back to reference Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993, 67: 6642-6647.PubMedPubMedCentral Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993, 67: 6642-6647.PubMedPubMedCentral
16.
go back to reference Denner J: Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralizing antibodies. Hum Vaccin. 2011, 7: 4-9. 10.4161/hv.7.0.14555.PubMedCrossRef Denner J: Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralizing antibodies. Hum Vaccin. 2011, 7: 4-9. 10.4161/hv.7.0.14555.PubMedCrossRef
17.
go back to reference Behrendt R, Fiebig U, Kurth R, Denner J: Induction of antibodies binding to the membrane proximal external region (MPER) of gp36 of HIV-2. Intervirology. 2012, 55: 252-256. 10.1159/000324483.PubMedCrossRef Behrendt R, Fiebig U, Kurth R, Denner J: Induction of antibodies binding to the membrane proximal external region (MPER) of gp36 of HIV-2. Intervirology. 2012, 55: 252-256. 10.1159/000324483.PubMedCrossRef
18.
go back to reference Mühle M, Bleiholder A, Kolb S, Hübner J, Löchelt M, Denner J: Immunological properties of the transmembrane envelope protein of the feline foamy virus and its use for serological screening. Virology. 2011, 412: 333-340. 10.1016/j.virol.2011.01.023.PubMedCrossRef Mühle M, Bleiholder A, Kolb S, Hübner J, Löchelt M, Denner J: Immunological properties of the transmembrane envelope protein of the feline foamy virus and its use for serological screening. Virology. 2011, 412: 333-340. 10.1016/j.virol.2011.01.023.PubMedCrossRef
19.
go back to reference Bellamy-McIntyre AK, Lay CS, Baär S, Maerz AL, Talbo GH, Drummer HE, et al: Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem. 2007, 282: 23104-23116. 10.1074/jbc.M703485200.PubMedCrossRef Bellamy-McIntyre AK, Lay CS, Baär S, Maerz AL, Talbo GH, Drummer HE, et al: Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem. 2007, 282: 23104-23116. 10.1074/jbc.M703485200.PubMedCrossRef
20.
go back to reference Noah E, Biron Z, Naider F, Arshava B, Anglister J: The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry. 2008, 47: 6782-6792. 10.1021/bi7023139.PubMedPubMedCentralCrossRef Noah E, Biron Z, Naider F, Arshava B, Anglister J: The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry. 2008, 47: 6782-6792. 10.1021/bi7023139.PubMedPubMedCentralCrossRef
21.
go back to reference Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W: Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6: e1000880-10.1371/journal.ppat.1000880.PubMedPubMedCentralCrossRef Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W: Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6: e1000880-10.1371/journal.ppat.1000880.PubMedPubMedCentralCrossRef
22.
go back to reference Lee SY, Howard TM, Rasheed S: Genetic analysis of the rat leukemia virus: influence of viral sequences in transduction of the c-ras proto-oncogene and expression of its transforming activity. J Virol. 1998, 72: 9906-9917.PubMedPubMedCentral Lee SY, Howard TM, Rasheed S: Genetic analysis of the rat leukemia virus: influence of viral sequences in transduction of the c-ras proto-oncogene and expression of its transforming activity. J Virol. 1998, 72: 9906-9917.PubMedPubMedCentral
23.
go back to reference De Lamarter JF, Monckton RP, Moroni C: Transcriptional control of endogenous virus genes in murine lymphocytes. J Gen Virol. 1981, 52: 371-375. 10.1099/0022-1317-52-2-371.CrossRef De Lamarter JF, Monckton RP, Moroni C: Transcriptional control of endogenous virus genes in murine lymphocytes. J Gen Virol. 1981, 52: 371-375. 10.1099/0022-1317-52-2-371.CrossRef
24.
go back to reference Stoye JP, Moroni C: Endogenous retrovirus expression in stimulated murine lymphocytes. Identification of a new locus controlling mitogen induction of a defective virus. J Exp Med. 1983, 157: 1660-1674. 10.1084/jem.157.5.1660.PubMedCrossRef Stoye JP, Moroni C: Endogenous retrovirus expression in stimulated murine lymphocytes. Identification of a new locus controlling mitogen induction of a defective virus. J Exp Med. 1983, 157: 1660-1674. 10.1084/jem.157.5.1660.PubMedCrossRef
25.
go back to reference Hirsch MS, Phillips SM, Solnik C, Black PH, Schwartz RS, Carpenter CB: Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci USA. 1972, 69: 1069-1072. 10.1073/pnas.69.5.1069.PubMedPubMedCentralCrossRef Hirsch MS, Phillips SM, Solnik C, Black PH, Schwartz RS, Carpenter CB: Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci USA. 1972, 69: 1069-1072. 10.1073/pnas.69.5.1069.PubMedPubMedCentralCrossRef
26.
go back to reference Denner J, Dorfman N: Small virus-like particles in leukosis-like syndrome induced by certain antigens and immunostimulators. Acta Biol Med German. 1977, 36: 1451-1458.PubMed Denner J, Dorfman N: Small virus-like particles in leukosis-like syndrome induced by certain antigens and immunostimulators. Acta Biol Med German. 1977, 36: 1451-1458.PubMed
27.
go back to reference Nelson M, Nelson DS, Spradbrow PB, Kuchroo VK, Jennings PA, Cianciolo GJ, Snyderman R: Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. Clin Exp Immunol. 1985, 61: 109-117.PubMedPubMedCentral Nelson M, Nelson DS, Spradbrow PB, Kuchroo VK, Jennings PA, Cianciolo GJ, Snyderman R: Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. Clin Exp Immunol. 1985, 61: 109-117.PubMedPubMedCentral
28.
go back to reference Büscher K, Hahn S, Hofmann M, Trefzer U, Ozel M, Sterry W, Löwer J, Löwer R, Kurth R, Denner J: Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res. 2006, 16: 223-234. 10.1097/01.cmr.0000215031.07941.ca.PubMedCrossRef Büscher K, Hahn S, Hofmann M, Trefzer U, Ozel M, Sterry W, Löwer J, Löwer R, Kurth R, Denner J: Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res. 2006, 16: 223-234. 10.1097/01.cmr.0000215031.07941.ca.PubMedCrossRef
29.
go back to reference Ramsoondar J, Vaught T, Ball S, et al: Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Xenotransplantation. 2009, 16: 164-180. 10.1111/j.1399-3089.2009.00525.x.PubMedCrossRef Ramsoondar J, Vaught T, Ball S, et al: Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Xenotransplantation. 2009, 16: 164-180. 10.1111/j.1399-3089.2009.00525.x.PubMedCrossRef
30.
go back to reference Semaan M, Kaulitz D, Petersen B, Niemann H, Denner J: Long-term effects of PERV-specific RNA interference in transgenic pigs. Xenotransplantation. 2012, 19: 112-121. 10.1111/j.1399-3089.2012.00683.x.PubMedCrossRef Semaan M, Kaulitz D, Petersen B, Niemann H, Denner J: Long-term effects of PERV-specific RNA interference in transgenic pigs. Xenotransplantation. 2012, 19: 112-121. 10.1111/j.1399-3089.2012.00683.x.PubMedCrossRef
31.
go back to reference Marciani DJ, Kensil CR, Beltz GA, Hung CH, Cronier J, Aubert A: Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine. 1991, 9: 89-96. 10.1016/0264-410X(91)90262-5.PubMedCrossRef Marciani DJ, Kensil CR, Beltz GA, Hung CH, Cronier J, Aubert A: Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine. 1991, 9: 89-96. 10.1016/0264-410X(91)90262-5.PubMedCrossRef
32.
go back to reference Denner J, Specke V, Thiesen U, Karlas A, Kurth R: Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. Virology. 2003, 314: 125-133. 10.1016/S0042-6822(03)00428-8.PubMedCrossRef Denner J, Specke V, Thiesen U, Karlas A, Kurth R: Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. Virology. 2003, 314: 125-133. 10.1016/S0042-6822(03)00428-8.PubMedCrossRef
33.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.PubMedCrossRef Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.PubMedCrossRef
Metadata
Title
Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs)
Authors
Joachim Denner
Debora Mihica
Danny Kaulitz
Christa-Maria Schmidt
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-260

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.